Kukje Pharm announced on the 28th that it held the 64th regular general meeting of shareholders in the auditorium of its headquarters on the 25th.
At the general shareholders’ meeting on the same day, executive directors Nam Young-woo and Kim Seong-gyu, and outside directors Choi Pil-sung, Lee Ga-won, and Jeon Seong-soo, whose terms had expired, were re-appointed respectively.
At the shareholders’ meeting, Kukje Pharm set the management keyword for this year as ‘profit management first,’ and pledged to do its best to increase profits.
Ahn Jae-man, CEO of Kukje Pharm, said, “This year, I will improve efficiency with the confidence that I can do everything well, the pride that I am an expert, and the habit of achieving, and develop crisis management skills through choice and concentration.” It is a difficult situation, but we will do our best to overcome difficult times and increase profits.”
He continued, “In particular, we plan to launch new products such as alepatadine eye drop 0.7% for the treatment of allergic conjunctivitis, Bro-eye eye drop for blepharitis and conjunctivitis, and Tenel DM Seo-release tablet for diabetes treatment. said.
Meanwhile, Kukje Pharmaceutical conducted a free capital increase at the rate of 0.05 shares per share as of the 21st of last year to improve the value of shareholders. The expected listing date of the new shares is April 11th.
